Sensitivity of pathogenic and opportunistic microorganisms to probiotic strains in the light of personalized probiotic therapy
- Authors: Parakhina A.I.1, Parakhina L.I.1, Troshina D.A.2, Levina K.E.2, Pimenova Y.A.1, Koteneva E.N.1, Evstropov A.N.1, Zakharova L.N.1, Mironov A.Y.3,4, Suranova T.G.4
-
Affiliations:
- Novosibirsk State Medical University
- Center of Hygiene and Epidemiology in the Novosibirsk Region
- Moscow Research Institute of Epidemiology and Microbiology named after G.N. Gabrichevsky
- Academy of Postgraduate Education of the Federal Scientific and Clinical Center for Specialized Types of Medical Care and Medical Technologies
- Issue: Vol 27, No 5 (2022)
- Pages: 280-289
- Section: ORIGINAL STUDIES
- URL: https://rjeid.com/1560-9529/article/view/117545
- DOI: https://doi.org/10.17816/EID117545
- ID: 117545
Cite item
Abstract
BACKGROUND: Resistance of microorganisms to antimicrobial drugs (AMP) is one of the global problems of modern medicine, which poses a serious threat to human health. The formation of the resistance of pathogens to AMP forces us to look for new ways to combat them. Probiotic therapy is one of the promising and safe methods of treating many infectious diseases.
AIM: This study assesses the sensitivity of clinical strains of pathogenic and opportunistic bacteria and fungi to microorganisms that are part of probiotic preparations.
MATERIALS AND METHODS: The sensitivity of 93 cultures of pathogenic and opportunistic microorganisms (UPM) isolated from the feces of patients with intestinal dysbiosis to strains of probiotic bacteria isolated from commercial probiotic preparations was studied: Lactobacillus plantarum 8RA-3, Escherichia coli M-17, Bacillus subtilis strain VKPM B-10641, Enterococcus faecium SF-68, Saccharomyces boulardii CNCM I-745 by the delayed antagonism method.
RESULTS: Pathogenic microorganisms showed low and moderate sensitivity to the probiotic strain of L. plantarum. Sensitivity to the probiotic strain of B. subtilis was detected in Staphylococcus aureus strains, low or completely absent in Pseudomonas aeruginosa, Klebsiella spp., Serratia marcescens. The most sensitive to the probiotic strain were clinical strains of E. coli.
CONCLUSION: UPM and pathogenic microorganisms isolated from the gastrointestinal tract of patients with dysbiosis have different sensitivity to probiotic strains: from high to several probiotics to its complete absence. The empirical approach to prescribing a probiotic does not guarantee a therapeutic effect, which makes it prudent to individualize the selection of a probiotic based on an assessment of its antimicrobial activity against isolated pathogens.
Keywords
Full Text
About the authors
Anastasia I. Parakhina
Novosibirsk State Medical University
Email: an.parakhina@mail.ru
ORCID iD: 0000-0003-1108-0811
Russian Federation, Novosibirsk
Larisa I. Parakhina
Novosibirsk State Medical University
Email: myinspirationmy@mail.ru
ORCID iD: 0000-0003-2428-9032
Russian Federation, Novosibirsk
Darya A. Troshina
Center of Hygiene and Epidemiology in the Novosibirsk Region
Email: troshina.darya92@mail.ru
ORCID iD: 0000-0003-3658-2674
Russian Federation, Novosibirsk
Katerina E. Levina
Center of Hygiene and Epidemiology in the Novosibirsk Region
Email: pumpum235@gmail.ru
ORCID iD: 0000-0001-6550-2931
Russian Federation, Novosibirsk
Yulia A. Pimenova
Novosibirsk State Medical University
Email: medic.81@mail.ru
ORCID iD: 0000-0001-8722-2746
SPIN-code: 6979-3750
MD, Cand. Sci. (Med.), Associate Professor
Russian Federation, NovosibirskElena N. Koteneva
Novosibirsk State Medical University
Email: lenakoteneva@rambler.ru
ORCID iD: 0000-0002-9901-2292
SPIN-code: 6638-0005
MD
Russian Federation, NovosibirskAleksandr N. Evstropov
Novosibirsk State Medical University
Email: evstrop@gmail.com
ORCID iD: 0000-0002-1551-3154
SPIN-code: 1747-5483
MD, Dr. Sci. (Med.), Professor
Russian Federation, NovosibirskLiudmila N. Zakharova
Novosibirsk State Medical University
Email: nisngma@ngs.ru
ORCID iD: 0000-0001-6051-2380
SPIN-code: 8610-8837
MD, Cand. Sci. (Med.), Associate Professor
Russian Federation, NovosibirskAndrey Yu. Mironov
Moscow Research Institute of Epidemiology and Microbiology named after G.N. Gabrichevsky; Academy of Postgraduate Education of the Federal Scientific and Clinical Center for Specialized Types of Medical Care and Medical Technologies
Email: andy.60@mail.ru
ORCID iD: 0000-0002-8544-5230
SPIN-code: 9225-1560
MD, Dr. Sci. (Med.), Professor
Russian Federation, Moscow; MoscowTatyana G. Suranova
Academy of Postgraduate Education of the Federal Scientific and Clinical Center for Specialized Types of Medical Care and Medical Technologies
Author for correspondence.
Email: suranovatatiana@mail.ru
ORCID iD: 0000-0003-3411-1027
SPIN-code: 7326-5273
MD, Cand. Sci. (Med.), Associate Professor
Russian Federation, MoscowReferences
- Danilov AI, Zharkova LP. Antibiotic resistance: arguments and facts. Clinical Pharmacology and Therapy. 2017;26(5):6–9. (In Russ).
- Vorobiev AA, Bykov AS, Boichenko MN, et al. Medical microbiology, virology and immunology. 3rd ed. Moscow: Meditsinskoye informatsionnoye agentstvo; 2022. 704 p. (In Russ).
- Satybaeva RT. Indications for use and evidence-based basis for the choice of probiotics in the practice of a pediatrician. Medicine (Almaty). 2018;(1):28–34. (In Russ).
- Bombaywala S, Mandpe A, Paliya S, Kumar S. Antibiotic resistance in the environment: a critical insight on its occurrence, fate, and eco-toxicity. Environ Sci Pollut Res Int. 2021;28(20): 24889–24916. doi: 10.1007/s11356-021-13143-x
- Belushkina NN, Chemezov AS, Paltsev MA. Personalized medicine: from idea to implementation in practical healthcare. Molecular Medicine. 2018;(3):9–15. doi: 10.29296/24999490-2018-03-02
- Zatevalov AM, Oganesyan AS, Gudova NV, et al. Practical application of microbiome-associated metabolomics for the integral assessment of the state of the microbiocenosis of the respiratory tract. In: Prospects for the implementation of innovative technologies in medicine and pharmacy: collection of materials of the 6th All-Russian scientific and practical conference with international participation; Orekhovo-Zuyevo, November 29, 2019. Orekhovo-Zuyevo: State University for the Humanities and Technology; 2019. P:77–84. (In Russ).
- General pharmacopoeial article 1.7.1.0008.15 Probiotics. In: State Pharmacopoeia of the Russian Federation. 14th ed. Moscow; 2018. Vol. 2. P:2596–2609. (In Russ).
- Zabokritsky NA. Biologically active substances synthesized by probiotic microorganisms of the genera Bacillus and Lactobacillus. Health and Education Millenium. 2015;17(3):80–90. (In Russ).
- Suez J, Zmora N, Segal E, Elinav E. The pros, cons, and many unknowns of probiotics. Nat Med. 2019;25(5):716–729. doi: 10.1038/s41591-019-0439-x
- Sanders ME, Akkermans LM, Haller D, et al. Safety assessment of probiotics for human use. Gut Microbes. 2010;1(3):164–185. doi: 10.4161/gmic.1.3.12127
- Martinelli M, Banderali G, Bobbio M, et al. Probiotics’ efficacy in paediatric diseases: which is the evidence? A critical review on behalf of the Italian Society of Pediatrics. Ital J Pediatr. 2020;46(1):104. doi: 10.1186/s13052-020-00862-z. Erratum in: Ital J Pediatr. 2020;46(1):116.
- Patent RUS №2702229/ 07.10.2019. Zaynullina ON, Khismatullina ZR, Pechkurov DV, Lyamin AV. Sposob lecheniya atopicheskogo dermatita u detey probioticheskimi preparatami s uchotom rezul’tatov mikrobiologicheskogo issledovaniya kala. Available from: https://yandex.ru/patents/doc/RU2702229C1_20191007 (In Russ).
- Ermolenko KD, Boldyreva NP, Martens EA, et al. The need for individual selection of probiotics containing lactobacilli and enterococci to increase the effectiveness of therapy for campylobacteriosis. Experimental and Clinical Gastroenterology. 2021;(2):88–93. (In Russ). doi: 10.31146/1682-8658-ecg-186-2-88-93
- Brunser O. Inocuidad, prevención y riesgos de los probióticos. Rev Chil Pediatr. 2017;88(4):534–540. doi: 10.4067/S0370-41062017000400015
- Chicherin IYu, Pogorelsky IP, Lundovskikh IA, et al. Evolution of probiotics: historical assessment and perspective. Diary of the Kazan Medical School. 2015;(1):42–51. (In Russ).
- Zawistowska-Rojek A, Tyski S. Are Probiotic Really Safe for Humans? Pol J Microbiol. 2018;67(3):251–258. doi: 10.21307/pjm-2018-044
- Sniffen JC, McFarland LV, Evans CT, Goldstein EJC. Choosing an appropriate probiotic product for your patient: An evidence-based practical guide. PLoS One. 2018;13(12):e0209205. doi: 10.1371/journal.pone.0209205
- Kryakvina EV, Neborskaya YuA, Martirosyan EA, et al. Antagonistic activity of probiotic strains of lactobacilli against fungi of the species Candida albicans under conditions of co-cultivation. International Student Scientific Bulletin. 2018;(6):68. (In Russ).
- Postnikova EA, Efimov BA, Volodin NN, Kafarskaya LI. Search for promising strains of bifidobacteria and lactobacilli for the development of new biological products. Journal of Microbiology, Epidemiology and Immunology. 2004;(2):64–69. (In Russ).
- Pilipenko VI. Saccharomyces boulardii is a source of signaling molecules. Questions of Dietology. 2014;4(2):30–37. (In Russ).
- Kaibysheva VO, Nikonov EL. Probiotics from the standpoint of evidence-based medicine. Russian Journal of Evidence-Based Gastroenterology. 2019;8(3):45–54. (In Russ). doi: 10.17116/dokgastro2019803145
- Savustyanenko AV. Mechanisms of action of probiotics based on Bacillus subtilis. Actual Infectology. 2016;(2):35–44. (In Russ).
- Kuznetsova MV, Maslennikova IL, Žgur-Bertok D, Starčič EM. Conjugative gene transfer of bacteriocins is a new mechanism of antimicrobial action of probiotic preparations. Bulletin of the Perm Scientific Center. 2017;(4):45–52. (In Russ). doi: 10.7242/1998-2097/2017.4.7
- Gritsenko VA, Mrugova TM, Kurlaev PP, et al. Antagonistic relationships of Pseudomonas aeruginosa with Gram-negative bacteria. Bulletin of the Orenburg Scientific Center of the Ural Branch of the Russian Academy of Sciences. 2016;(4):5. (In Russ).